Alka-Seltzer
(Sodium Bicarbonate)ApprovedSmall molecule
Sodium bicarbonate is used to treat heartburn and acid indigestion by neutralizing stomach acid, and it can also help balance the pH of your blood in certain medical conditions.[2] Alka-Seltzer is currently approved and in use across 43 indications[4].[1]
Alka-Seltzer is one of 655 small molecule programs targeting Myocardial Infarction. It is currently in Approved.
43
Indications
99
Total Trials
20
Active Trials
654
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 38 indications
Competition
Competitive Landscape
350 competitors in Treatment
#DrugCompanyPhaseTrials
1Alka-Seltzer
AAbbott
Approved
Alfenta
Jazz PharmaceuticalsPreclinical
Theo-Dur
PfizerPreclinical
Levulan
Sun Pharmaceutical Industries, Inc.Preclinical
Lamprene
NovartisPreclinical
Emtriva
GileadPreclinical
Hivid
CConrado Roberto Hoffmann Filho
Preclinical
Foscavir
CClinigen, Inc.
Preclinical
Valium
Akero TherapeuticsPreclinical
Reminyl
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Nephropathy14 trials
Show 11 more trials
The Use of Sodium Bicarbonate in the Prevention of Contrast Induced Nephropathy
Terminated·—·N/A·NCT00494637·468 enrolled
A Prospective Study on Incidence and Prevention of Contrast-induced Nephropathy in Croatia
Completed·—·Phase 4·NCT02761577·90 enrolled
Prevention of Contrast Induced Nephropathy in Oncology Patients With Sodium Bicarbonate
Completed·—·Phase 2·NCT00540904·27 enrolled
Sodium Bicarbonate for Prevention of Contrast-Induced Nephropathy
Completed·—·Phase 3·NCT01172353·301 enrolled
Chronic Kidney Disease7 trials
Alkali Therapy in Chronic Kidney Disease
Completed·—·Phase 2/3·NCT01452412·149 enrolled
Show 4 more trials
Sodium Bicarbonate Supplementation in Chronic Kidney Disease Evaluation of Dose Response, Safety and Beneficial Effects
Completed·—·Phase 2/3·NCT00888290·20 enrolled
Acid-Base Compensation in Chronic Kidney Disease
Completed·—·Phase 1·NCT02427594·14 enrolled
Acute Kidney Injury4 trials
Show 1 more trial
Prevention of Acute Kidney Injury in Cardiac Surgery Patients
Completed·—·Phase 2·NCT00921518·92 enrolled
Kidney Transplant3 trials
58 more indications
Cardiac Arrest3 trials
Bicarbonate in Patients With Out-of-hospital Cardiac Arrest
Completed·—·Phase 2·NCT02303548·50 enrolled
Cardiac Surgery3 trials
Local Anesthesia2 trials
Acute Myocardial Infarction2 trials
COVID-192 trials
After Cardiac Surgery2 trials
Preventing Acute Renal Failure After Cardiac Surgery in High Risk Patients Using Sodium Bicarbonate Therapy
Unknown status·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 3·NCT00522756·200 enrolled
Metabolic Acidosis2 trials
SODium BICarbonate for Metabolic Acidosis in the ICU
Active, not recruiting·—·Phase 3·NCT05697770·500 enrolled
Gastric Cancer1 trial
Intra-arterial Infusion Chemotherapy Combined With Sodium Bicarbonate for Unresectable Gastric Cancer
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT03822130·150 enrolled
TED1 trial
Efficacy1 trial
Oral Mucositis1 trial
Sickle Cell Disease1 trial
Uric Acid1 trial
Infective Endocarditis1 trial
Kidney Disease1 trial
Interaction1 trial
Coronary Artery Bypass1 trial
Infiltration1 trial
Prospective1 trial
Prolonged1 trial
Efficacy of Bicarbonate on the Risk of Assisted Delivery in Nulliparous Women With Prolonged Labour
Not yet recruiting·—·N/A·NCT07321379·1,520 enrolled
Systemic Inflammatory Response Syndrome1 trial
Complication1 trial
Comparison of Effectiveness and Complications of Catheter Lock Solutions in Non-tunneled Hemodialysis Catheters
Completed·—·N/A·NCT04772209·441 enrolled
Type 1 Diabetes1 trial
Critically Ill Patients1 trial
Intravenous1 trial
Cognitive Function1 trial
Treatment1 trial
Tics1 trial
Hypertension1 trial
Sodium Bicarbonate in Intra-dialytic Hypertension in Chronic Hemodialysis Patients
Not yet recruiting·—·Phase 2/3·NCT07231900·40 enrolled
Microbial Colonization1 trial
Autosomal Dominant Polycystic Kidney Disease1 trial
Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease
Enrolling by invitation·TTaipei Medical University Shuang Ho Hospital·Phase 2·NCT05870007·30 enrolled
Dialysis Patients1 trial
Botulinum Toxin1 trial
Pulpitis1 trial
Efficacy and Safety1 trial
Efficacy and Safety of Sodium Hyaluronate Gel Combined With Sodium Bicarbonate Versus Sodium Bicarbonate Alone in Prevention of Failed Back Surgery Syndrome
Active, not recruiting·MMisr University for Science and Technology·Phase 2/3·NCT06999993·60 enrolled
Hyperuricemia1 trial
Pulmonary Edema1 trial
Pneumonia1 trial
Myocardial Infarction1 trial
Pain Perception1 trial
Chronic Kidney Diseases1 trial
Dermatochalasis1 trial
Regulatory
FDA Approval Timeline[5]
Jun 3, 1986
SODIUM BICARBONATE IN PLASTIC CONTAINER
NDA NDA019443
Jul 8, 2026
SODIUM BICARBONATE
NDA NDA220790
Aug 14, 2026
SODIUM BICARBONATE
NDA NDA218524
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Alka-Seltzer drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Sodium Bicarbonate. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]